 | Drug Safety update MHRA February-2021-DSU-PDF_final.pdf (300KB) | 23/02/2021 | Download |
| | Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury. injury page 2 Pregabalin (Lyrica): reports of severe respiratory depression. Alkindi (hydrocortisone... | |
| Drug Safety Update MHRA January 2021 PDF.pdf (361KB) | 07/01/2021 | Download |
| | Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review page: COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice. Dimethyl fumarate... | |
| Drug Safety Update MHRA December 2020-DSU-PDF-1712.pdf (263KB) | 18/12/2020 | Download |
| | Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk: Erythromycin: caution required due to cardiac risks (QT... | |
| Drug Safety Update MHRA November 2020 PDF.pdf (308KB) | 16/11/2020 | Download |
| | Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy. Pirfenidone (Esbriet): risk of serious liver injury, and updated advice on liver function testing . Ferric... | |
| Drug Safety Update MHRA October 2020.pdf (295KB) | 22/10/2020 | Download |
| | 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity. Flucytosine (Ancotil): new... | |
| Drug Safety Update MHRA September 2020 PDF.pdf (279KB) | 24/09/2020 | Download |
| | Opioids: risk of dependence and addiction: Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients: Methotrexate once-weekly for autoimmune diseases: new measures to... | |
| Drug Safety Update MHRA August 2020-DSU-PDF.pdf (306KB) | 01/09/2020 | Download |
| | Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available over-the-counter: new measures to support safe use. Clozapine and other antipsychotics: monitoring blood... | |
| Drug Safety Update MHRA July-2020-DSU-PDF.pdf (203KB) | 31/07/2020 | Download |
| | Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection. Liposomal and lipid-complex formulations: name change to reduce medication errors | |
| Drug Safety Update MHRA June-2020-DSU-PDF.pdf (286KB) | 29/06/2020 | Download |
| | | |
| Drug Safety Update MHRA May-2020-DSU.pdf (244KB) | 21/05/2020 | Download |
| | | |
| Drug Safety Update MHRA April-2020 PDF.pdf (194KB) | 28/04/2020 | Download |
| | | |
| Drug Safety Update MHRA March-2020-PDF.pdf (301KB) | 07/04/2020 | Download |
| | Esmya - licence suspended: tofacitinib [Xeljanz] - new measures to minimise risk of VTE & of serious and fatal infections: Baricitinib - risk of venous thromboembolism | |
